Abstract:Hypoxia imaging agents can play an important role in the tumor treatment by avoiding the worse effect of radiotherapy and chemotherapy due to the tumor hypoxia. Due to the small size and easy coordination, tricarbonyl technetium-99m can be used to label a wide range of imaging agents. In this work, the tricarbonyl Tc-99m labeled small-sized hypoxia imaging agents containing 2-nitroimidazoles were prepared, which have different carbon chain lengths between cyclopentadienyl and 2-nitroimidazole, and which have one or two 2-nitroimidazole groups. The results of S180 cell experiment and biodistribution indicated that these molecules have different hypoxic selectivity. When contains one 2-nitroimidazole, as the carbon chain lengthens, which means the molecular volume becomes larger, hypoxia cellular uptake and selectivity decrease in S180 cell uptake experiment. In biodistribution study in mice bearing S180 tumor, Tc-2 (1-cyclopentadienyl-5-(2-nitro-1H-imidazol-1-yl)-pentan-1-one tricarbonyl Tc-99m complex), which has intermediate carbon chain, is better due to the more complex factors. Its tumor/blood (T/B) ratio is 3.56 & PLUSMN; 0.25, tumor/muscle(T/M) ratio is 1.73 & PLUSMN; 0.29 and tumor uptake is 2.23 & PLUSMN; 0.24%ID/g at 2 h. Comparing to other tricarbonyl technetium complexes containing one 2-nitroimidazole, the complexes in this work have an advantage in tumor/blood ratio and tumor uptake. This suggests that the small-volume cyclopentadienyl may have an advantage when used as a ligand. When contains two 2nitroimidazole groups, the complex, 1-cyclopentadienyl-5-di(2-(2-nitro-1H-imidazol-1-yl)ethyl)amino-pentan1-one tricarbonyl Tc-99m complex (Tc-4), has the better results in the cell experiment than those which contain one 2-nitroimidazole group. Thus the hypoxia imaging agent contains two 2-nitroimidazole groups is more advantageous, but further modifications of Tc-4 are needed to improve its clearance rate in the blood, because the increased lipophilicity leads to a decrease in the T/B ratio of Tc-4. In conclusion, small volume hypoxia imaging agents with two 2-nitroimidazole groups may be the trend of development.

Preparation of two 99m Tc(CO) 3 labelled complexes with a 4-nitroimidazole isocyanide at different temperatures for molecular imaging of tumor hypoxia

Radiosynthesis and Evaluation of Novel [99mtc(i)]+ and [99mtc(i)(co)3]+ Complexes with a 4‐nitroimidazole Isocyanide for Imaging Tumor Hypoxia

Novel 99mtc Labelled Complexes with 2-Nitroimidazole Isocyanide: Design, Synthesis and Evaluation As Potential Tumor Hypoxia Imaging Agents.

Synthesis and evaluation of [<SUP>99m</SUP>TcN]<SUP>2+</SUP> core and [<SUP>99m</SUP>TcO]<SUP>3+</SUP> core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Synthesis and evaluation of [99mTcN]2+ core and [99mTcO]3+ core labeled complexes with 4-nitroimidazole xanthate derivative for tumor hypoxia imaging

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Preparation and Bioevaluation of Novel 99Mtc-Labeled Complexes with a 2-Nitroimidazole HYNIC Derivative for Imaging Tumor Hypoxia

Synthesis and Evaluation of <SUP>99m</SUP>Tc-Labelled 2-Nitroimidazole Derivatives with Different Linkers for Tumour Hypoxia Imaging

[Tc-99M(co)(3)](+) Labeled Histidine Derivative Containing 4-Nitroimidazole: Synthesis, Biodistribution As A Tumor Hypoxia Imaging Agent

Preparation and Biological Evaluation of Two Novel Tc-99m-nitrido Complexes of Metronidazole Derivative for Targeting Hypoxia

Novel 99m Tc-labelled complexes with thymidine isocyanide: radiosynthesis and evaluation as potential tumor imaging tracers.

Preparation and biological evaluation of two novel 99mTc-nitrido complexes of metronidazole derivative for targeting hypoxia

Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia

A thiourea‐bridged 99mTc(CO)3‐dipicolylamine‐2‐nitroimidazole complex for targeting tumor hypoxia: Utilizing metabolizable thiourea‐bridge to improve pharmacokinetics

Preparation and Biological Evaluation of a Technetium-99M Labeled 4-Nitroimidazole Derivative for Imaging Tumor Hypoxia

Preparation and bioevaluation of a novel 99m Tc-labelled propylene amine oxime (PnAO) containing two 4-methyl-2-nitroimidazole groups as a promising tumor hypoxia imaging agent

Preparation and Biodistribution of Technetium-99m-Labeled Bis-Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia.

Synthesis and Preliminary Biological Evaluation of 99m Tc(CO) 3 -Labeled Pegylated 2-Nitroimidazoles

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

In Vitro and in Vivo Evaluation of A Technetium-99m-Labeled 4-Nitroimidazole As A Tracer for Detection of Tumor Hypoxia

Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging